LONG $ARRY

٩ مايو ٢٠١٧

ARRY has been going down for too long since they they withdrawn their FDA application for its skin cancer drug binimetinib after poor P3 results.
Stock seems oversold atm. Yesterday's results were quite positive. May have a short squeeze.